This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugarbaker, P. H. Articles by Chang, D. Search for Related Content PubMed PubMed Citation Articles by Sugarbaker, P. H. Articles by Chang, D.

Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy

¹ Washington Cancer Institute, 106 Irving Street, N.W., Suite 3900, Washington, District of Columbia 20010
² Westat, 1441 West Montgomery Avenue, Rockville, Maryland 20850–2062

Correspondence: Address correspondence and reprint requests to: Paul H. Sugarbaker, MD, FACS, FRCS; E-mail: paul.sugarbaker{at}medstar.net.

Background: Appendiceal mucinous neoplasms present, in most patients, with peritoneal dissemination at the time of initial diagnosis. Patients may have a borderline tumor showing disseminated peritoneal adenomucinosis or an aggressive malignancy identified as peritoneal mucinous adenocarcinoma. Patients with these diagnoses were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.

Methods: A database was established in 1998 that prospectively evaluated the morbidity and mortality of this group of patients. By using common toxicity grading criteria, 8 categories were scored on a grade of I to V. Grade IV indicated that the adverse event required urgent and definitive intervention: often a return to the operating room or to the surgical intensive care unit. Grade V indicated that the adverse events resulted in the patient’s death. Adverse events were tabulated for each cytoreduction performed in these appendiceal malignancy patients.

Results: There were 356 procedures in patients taken to the operating room who received cytoreductive surgery with peritonectomy procedures plus heated intraoperative intraperitoneal chemotherapy. Only patients who had this combined treatment at our institution were included in the analysis. The total 30-day or inshospital mortality was 2.0%. Nineteen percent of procedures were accompanied by at least one grade IV adverse event, and 11.1% of patients returned to the operating room. The most common category of grade IV complications was hematological (28%), followed by gastrointestinal (26%).

Conclusions: The mortality of 2.0% and the overall grade IV morbidity of 19% in these patients may be acceptable in light of modern standards for the management of gastrointestinal cancer.

Key Words: Cytoreductive surgery • Hyperthermia • Peritonectomy • Intraperitoneal chemotherapy • Mitomycin C • 5-Fluorouracil

This article has been cited by other articles:

				D. C. Gammon, T. Dutton, B. Piperdi, J. Zybert, S. H. Wolfe, E. Nguyen, D. Sbat, V. G. Pillarisetty, M. Sullivan, and G. F. Whalen Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis Am. J. Health Syst. Pharm., July 1, 2009; 66(13): 1186 - 1190. [Abstract] [Full Text] [PDF]

				E. Marcotte, L. Sideris, P. Drolet, A. Mitchell, S. Frenette, G. Leblanc, Y. E. Leclerc, and P. Dube Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin for Peritoneal Carcinomatosis Arising from Appendix: Preliminary Results of a Survival Analysis Ann. Surg. Oncol., October 1, 2008; 15(10): 2701 - 2708. [Abstract] [Full Text] [PDF]

				N. J. Gusani, S. W. Cho, C. Colovos, S. Seo, J. Franko, S. D. Richard, R. P. Edwards, C. K. Brown, M. P. Holtzman, H. J. Zeh, et al. Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center Ann. Surg. Oncol., March 1, 2008; 15(3): 754 - 763. [Abstract] [Full Text] [PDF]

				E. A. Levine, B. M. Ronnett, P. F. Mansfield, and C. Eng Overview of Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms ASCO Educational Book, January 1, 2008; 2008(1): 153 - 159. [Abstract] [Full Text] [PDF]

				E. A. Levine Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best Ann. Surg. Oncol., September 1, 2007; 14(9): 2440 - 2442. [Full Text] [PDF]

				T. D. Yan, M. Links, S. Fransi, T. Jacques, D. Black, V. Saunders, and D. L. Morris Learning Curve for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy A Journey to Becoming a Nationally Funded Peritonectomy Center Ann. Surg. Oncol., August 1, 2007; 14(8): 2270 - 2280. [Abstract] [Full Text] [PDF]

				T. D. Yan, L. Bijelic, and P. H. Sugarbaker Critical Analysis of Treatment Failure After Complete Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Dissemination From Appendiceal Mucinous Neoplasms Ann. Surg. Oncol., August 1, 2007; 14(8): 2289 - 2299. [Abstract] [Full Text] [PDF]